PACLITAXEL LOADED POLYLACTIDE-CO-GLYCOLIDE ACIDS FOR CORONARY ARTERY DISEASE AND CANCER TREATMENT

PACLITAXEL LOADED POLYLACTIDE-CO-GLYCOLIDE ACIDS FOR CORONARY ARTERY DISEASE AND CANCER TREATMENT

Abstract:
Coronary artery disease (CAD) and cancer remain significant health challenges worldwide. The development of effective therapies for these diseases is crucial to improve patient outcomes and quality of life. In recent years, the use of drug-eluting stents (DES) and targeted drug delivery systems has shown promise in treating both CAD and various types of cancer.

This abstract focuses on the potential of paclitaxel-loaded polylactide-co-glycolide acids (PLGA) as a versatile platform for the treatment of coronary artery disease and cancer. PLGA is a biocompatible and biodegradable polymer that has been extensively investigated for controlled drug release applications.

For coronary artery disease treatment, PLGA-based drug-eluting stents have gained significant attention. Paclitaxel, a potent anti-proliferative drug, has been widely used to inhibit neointimal hyperplasia and reduce restenosis rates after stent implantation. The incorporation of paclitaxel into PLGA stents allows sustained drug release, providing long-term inhibition of smooth muscle cell proliferation.

In cancer treatment, paclitaxel is known for its effectiveness against various solid tumors. However, its clinical utility is limited by poor solubility and systemic toxicity. PLGA nanoparticles have emerged as a promising strategy for enhanced drug delivery to tumors. Encapsulation of paclitaxel within PLGA nanoparticles improves its solubility, extends circulation time, and enables targeted delivery to tumor sites, thereby enhancing therapeutic efficacy while minimizing adverse effects.

The combination of paclitaxel and PLGA offers a dual-purpose platform for the treatment of both CAD and cancer. By tailoring the properties of PLGA, such as molecular weight, copolymer ratio, and drug loading capacity, the release kinetics and therapeutic outcomes can be optimized for specific applications.

In conclusion, paclitaxel-loaded PLGA-based systems hold great potential for the treatment of coronary artery disease and various types of cancer. Their controlled release properties, biocompatibility, and targeting capabilities make them attractive candidates for improving therapeutic outcomes and patient care in these challenging medical conditions. Further research and clinical investigations are warranted to fully explore the potential of these innovative drug delivery systems.

Keywords: Paclitaxel, polylactide-co-glycolide acids, PLGA, drug-eluting stents, coronary artery disease, cancer treatment, drug delivery, nanoparticles, controlled release.

PACLITAXEL LOADED POLYLACTIDE-CO-GLYCOLIDE ACIDS FOR CORONARY ARTERY DISEASE AND CANCER TREATMENT, GET MORE MATERIALS SCIENCE AND ENGINEERING

Sharing is caring!